NCT06894693View on ClinicalTrials.gov

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2028

Conditions
B-cell Non-Hodgkin's LymphomaAcute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

RS001 injection

CD19-CAR-mbIL15-DNT Cells.

All Listed Sponsors
lead

Guangdong Ruishun Biotech Co., Ltd

INDUSTRY